FONR Quote, Financials, Valuation and Earnings

OncoCyte has a net margin of 9.23% compared to Fonar's net margin of -312.02%. Fonar's return on equity of 5.33% beat OncoCyte's return on equity of -693.81%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand OncoCyte has an analysts' consensus of $5.42 which suggests that it could grow by 94.84%. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

Fonar has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.970, suggesting its less volatile than the S&P 500 by 3.025%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $27.2M, which are larger than OncoCyte quarterly revenues of $2.1M. Fonar's net income of $2.5M is higher than OncoCyte's net income of -$6.7M. Notably, Fonar's price-to-earnings ratio is 11.50x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 12.60x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 9.23% compared to Fonar's net margin of -209.38%. Fonar's return on equity of 5.33% beat ProPhase Labs's return on equity of -144.22%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3770.97%. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

Fonar has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.433, suggesting its less volatile than the S&P 500 by 143.298%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $27.2M, which are larger than ProPhase Labs quarterly revenues of $1.4M. Fonar's net income of $2.5M is lower than ProPhase Labs's net income of $4M. Notably, Fonar's price-to-earnings ratio is 11.50x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 1.93x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of 9.23% compared to Fonar's net margin of 6.16%. Fonar's return on equity of 5.33% beat Veracyte's return on equity of 2.85%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte has an analysts' consensus of $40.89 which suggests that it could grow by 46.82%. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Fonar has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison Veracyte has a beta of 2.093, suggesting its more volatile than the S&P 500 by 109.267%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $27.2M, which are smaller than Veracyte quarterly revenues of $114.5M. Fonar's net income of $2.5M is lower than Veracyte's net income of $7M. Notably, Fonar's price-to-earnings ratio is 11.50x while Veracyte's PE ratio is 67.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 4.75x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 9.23% compared to Fonar's net margin of -67.19%. Fonar's return on equity of 5.33% beat XWELL's return on equity of -153.74%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 678.04%. Given that XWELL has higher upside potential than Fonar, analysts believe XWELL is more attractive than Fonar.

Fonar has a beta of 0.993, which suggesting that the stock is 0.67700000000001% less volatile than S&P 500. In comparison XWELL has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.658%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $27.2M, which are larger than XWELL quarterly revenues of $7M. Fonar's net income of $2.5M is higher than XWELL's net income of -$4.7M. Notably, Fonar's price-to-earnings ratio is 11.50x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.89x versus 0.14x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.